fludarabine has been researched along with P carinii Pneumonia in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (33.33) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Haeusler, GM; Lingaratnam, S; Seymour, JF; Slavin, MA; Tam, CS; Teh, BW; Thursky, KA; Worth, LJ | 1 |
| Aguilar, J; Al-Katib, A; del Busto, R; Johnson, LB; Obeid, KM; Sharma, M; Szpunar, S | 1 |
| Bond, R; Brown, M; Campbell, P; Grigg, AP; Ritchie, D; Scarlett, J; Seymour, JF; Tam, C; Underhill, C | 1 |
| Huisman, CA; Laros-van Gorkom, BA; Schipperus, MR; Wijermans, PW | 1 |
| Byrd, JC; Diehl, LF; Hargis, JB; Hospenthal, DR; Kester, KE; Knutson, SW | 1 |
| Lawrence, HJ; Perez, EA; Sanders, C | 1 |
6 other study(ies) available for fludarabine and P carinii Pneumonia
| Article | Year |
|---|---|
Late-onset Pneumocystis jirovecii pneumonia post-fludarabine, cyclophosphamide and rituximab: implications for prophylaxis.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Leukemia, Lymphoid; Lymphoma; Male; Middle Aged; Pneumocystis carinii; Pneumonia, Pneumocystis; Rituximab; Treatment Outcome; Vidarabine | 2013 |
Risk factors for Pneumocystis jirovecii pneumonia in patients with lymphoproliferative disorders.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Case-Control Studies; Cladribine; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Lymphoproliferative Disorders; Male; Middle Aged; Pneumocystis carinii; Pneumonia, Pneumocystis; Retrospective Studies; Risk Factors; Time Factors; Treatment Outcome; Trimethoprim, Sulfamethoxazole Drug Combination; Vidarabine | 2012 |
Early and late infectious consequences of adding rituximab to fludarabine and cyclophosphamide in patients with indolent lymphoid malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Cyclophosphamide; Disease Susceptibility; Female; Herpesviridae Infections; Humans; Immunocompromised Host; Infections; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Pneumonia, Pneumocystis; Risk; Rituximab; Vidarabine | 2005 |
Experience with alemtuzumab in treatment of chronic lymphocytic leukaemia in the Netherlands.
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antigens, CD; Antigens, Neoplasm; Aspergillosis; CD52 Antigen; Drug Evaluation; Drug Resistance, Neoplasm; Glycoproteins; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Medical Records; Netherlands; Opportunistic Infections; Pneumonia, Pneumocystis; Remission Induction; Retrospective Studies; Surveys and Questionnaires; Treatment Outcome; Vidarabine | 2007 |
Opportunistic pulmonary infections with fludarabine in previously treated patients with low-grade lymphoid malignancies: a role for Pneumocystis carinii pneumonia prophylaxis.
Topics: Antineoplastic Agents; Biopsy; Bronchoscopy; Humans; Lung; Lung Diseases; Lymphoma, Non-Hodgkin; Multicenter Studies as Topic; Opportunistic Infections; Pneumonia, Pneumocystis; Vidarabine | 1995 |
Opportunistic infections in patients with chronic lymphocytic leukemia following treatment with fludarabine.
Topics: Antineoplastic Agents; Humans; Immunity, Cellular; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Opportunistic Infections; Pneumonia, Pneumocystis; Tuberculosis; Vidarabine | 1992 |